Business Description
Filana Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US14817C1071
Total Employee Number:
20Description
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.63 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | 0.4 | |||||
3-Year FCF Growth Rate | 30.2 | |||||
3-Year Book Growth Rate | -34.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.01 | |||||
9-Day RSI | 48.88 | |||||
14-Day RSI | 45.67 | |||||
3-1 Month Momentum % | -16.76 | |||||
6-1 Month Momentum % | -31.1 | |||||
12-1 Month Momentum % | -28.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.19 | |||||
Quick Ratio | 2.19 | |||||
Cash Ratio | 2.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -88.58 | |||||
ROA % | -61.56 | |||||
ROIC % | -384.2 | |||||
3-Year ROIIC % | 289.81 | |||||
ROC (Joel Greenblatt) % | -400.65 | |||||
ROCE % | -93.94 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 12.79 | |||||
PB Ratio | 0.88 | |||||
Price-to-Tangible-Book | 0.88 | |||||
EV-to-EBIT | 0.33 | |||||
EV-to-Forward-EBIT | 0.21 | |||||
EV-to-EBITDA | 0.33 | |||||
EV-to-Forward-EBITDA | 0.2 | |||||
EV-to-Forward-Revenue | 0.43 | |||||
EV-to-FCF | 0.91 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.29 | |||||
Earnings Yield (Greenblatt) % | 303.03 | |||||
FCF Yield % | -50.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FLNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Filana Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.61 | ||
| Beta | 0.6627 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.39 | ||
| Volatility % | 69.13 | ||
| 14-Day RSI | 45.67 | ||
| 14-Day ATR ($) | 0.080674 | ||
| 20-Day SMA ($) | 1.259 | ||
| 12-1 Month Momentum % | -28.36 | ||
| 52-Week Range ($) | 1.15 - 4.98 | ||
| Shares Outstanding (Mil) | 48.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Filana Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Filana Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 42 days | ||
| General meeting for 2026 | 2026-06-11 08:30 | 1.32 (-7.04%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.44 (+5.88%) | ||
| Annual report for 2025 | 2026-03-12 | 2.09 (-7.11%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 2.09 (-7.11%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 3.11 (-0.32%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-08 17:00 | 2.16 (+0.93%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.28 (+0.00%) | ||
| General meeting for 2025 | 2025-05-23 10:00 | 2.12 (+3.41%) |
Show
Entries
Filana Therapeutics Inc Frequently Asked Questions
What is Filana Therapeutics Inc(FLNA)'s stock price today?
The current price of FLNA is $1.24. The 52 week high of FLNA is $4.98 and 52 week low is $1.15.
When is next earnings date of Filana Therapeutics Inc(FLNA)?
The next earnings date of Filana Therapeutics Inc(FLNA) is 2026-08-14 Est..
Does Filana Therapeutics Inc(FLNA) pay dividends? If so, how much?
Filana Therapeutics Inc(FLNA) does not pay dividend.
Guru Commentaries on NAS:FLNA
No articles.
Press Release
Articles on Filana Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers